GlycoVaxyn is a clinical stage biopharmaceutical company focused on the development and manufacture of next-generation bioconjugate vaccines utilizing its proprietary recombinant DNA technology.

GlycoVaxyn's technology enables the development and production of immunogenic glycoproteins (polysaccharide and protein complexes) for use as conjugated vaccines. Our "bioconjugates" employ a well-known recombinant technology. The advantage of the technology is the ability to conjugate any carbohydrate to almost any protein resulting in a well-characterized molecule with high consistency and batch-to-batch reproducibility. As a result, GlycoVaxyn is able to target bacterial diseases for which effective and/or affordable vaccines do not currently exist.

GlycoVaxyn's pipeline includes bioconjugate vaccine candidates that target some of the most common and severe bacterial infections that occur in childhood and throughout life. The lead vaccine target, Shigella dysenteriae, a bacterial pathogen that causes travelers' diarrhea, has completed Phase 1 studies in healthy volunteers in which it elicited a robust immunogenic response. Other important targets, such as Staphylococcus aureus and Uropathogenic E.Coli, are in preclinical development.

GlycoVaxyn is a privately held Swiss biopharmaceutical company based in Schlieren, near Zurich, Switzerland. The company was founded in 2004 as a spin-out company from the Swiss Federal Institute of Technology (ETH) to commercialize the recombinant DNA glycoprotein technology developed by its scientific founder. The company currently employs 50 people.